Connect your AI

XOMA Corporation XOMA Stock-Based Comp

Stock-Based Comp at other companies

Ligand PharmaceuticalsLGND

$10.6M+35.2%

Theravance BiopharmaTBPH

$4.5M-7.6%

Innoviva, Inc.INVA

$2.57M+19.6%

ZymeworksZYME

$6.94M+8.3%

ALN

Alnylam PharmaceuticalsALNY

$70.15M+23.7%

XencorXNCR

$9.56M-21.7%

Other financials

Income statement

Revenue$12.3M-22.6%

Operating income-$480.0K-108%

Net income$4.5M+88.6%

EPS (diluted)$0.17+183%

Balance sheet

Cash & equivalents$85.6M-5.2%

Total debt$124.7M+9.0%

Total equity$92.9M+9.7%

Total assets$271.9M+27.8%

Cash flow

Operating cash flow$6.1M+178%

CapEx$3.0K-29.4%

Free cash flow-$2.9M+36.0%

Valuation

Market cap$746.04M+159%

Enterprise value$785.17M+152%

P/E22.1×—

P/S15.4×+8.7×

Profitability

Operating margin10.2%+5.5pp

Net margin69.6%+64.0pp

FCF margin-320%-118pp

Returns & leverage

Return on equity38.1%+35.2pp

Debt / equity1.3×0.0×

Current ratio3.6×-2.0×

Where this comes from

Reported directly by XOMA Corporation in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: XOMA Corporation’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about XOMA Corporation's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is XOMA Corporation's stock-based comp?: XOMA Corporation (XOMA) reported stock-based comp of $2.28M in Q1 2026.
How has XOMA Corporation's stock-based comp changed year-over-year?: XOMA Corporation's stock-based comp increased by 15.0% year-over-year, from $1.98M to $2.28M.
What is the long-term trend for XOMA Corporation's stock-based comp?: Over 4 years (2021 to 2025), XOMA Corporation's stock-based comp has grown at a 10.6% compound annual growth rate (CAGR), from $6.2M to $9.27M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.